Skip to content

Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures

Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02195622
Enrollment
74
Registered
2014-07-21
Start date
2013-09-30
Completion date
2016-02-29
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hypertrophy Requiring Surgical Intervention

Brief summary

To compare efficiency, in terms of tissue morcellation and removal time, of two commercially available FDA-approved morcellators: the VersaCut and the Piranha in subjects undergoing HoLEP procedure for benign prostatic hyperplasia (BPH).

Detailed description

Holmium laser enucleation of the prostate (HoLEP) with mechanical morcellation is a surgical technique used for treatment of bladder outlet obstruction (BOO) secondary to benign prostatic hyperplasia (BPH). HoLEP represents a state of the art alternative to transurethral resection of the prostate (TURP). HoLEP has been shown to be safe and effective for treating prostates of all sizes and has low perioperative morbidity. A holmium laser fiber is passed through a continuous-flow resectoscope and is used to resect the obstructing prostate tissue (enucleation). After enucleation is performed, the resected tissue is advanced into the bladder. The morcellator is then used to cut the tissue into small pieces which are then removed from the bladder via suction through the morcellator blades (morcellation). We currently use the first commercially available morcellator (VersaCut, Lumenis Incorporated, Santa Clara, CA). The Storz continuous-flow resectoscope (Karl Storz,Tuttlingen, Germany) is currently used to perform the enucleation portion of the procedure. Recently, a new morcellator has been developed (Piranha, Richard Wolf, Knittlingen, Germany). The Wolf morcellator has been reported to remove tissue at a faster rate than the Lumenis device

Interventions

DEVICELumenis VersaCut Morcellator
DEVICEWolf Piranha Morcellator

Sponsors

Richard Wolf Medical Instruments Corporation (RWMIC)
CollaboratorUNKNOWN
Indiana Kidney Stone Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients scheduled to undergo HoLEP for bladder outlet obstruction due to the prostate. * Able to give informed consent. * Age 18 years or older

Exclusion criteria

* • Inability to give informed consent. * Age less than 18 years

Design outcomes

Primary

MeasureTime frameDescription
Morcellation RateCollected intraoperatively upon completion of enucleation (surgical removal) of the extra benign prostate tissue growthOperatively, the amount of enucleated tissue removed (in grams) per the time for complete removal (in minutes) will be recorded as morcellation rate.

Countries

United States

Participant flow

Participants by arm

ArmCount
Lumenis VersaCut Morcellator
Lumenis VersaCut Morcellator will be utilized for prostate tissue morcellation Lumenis VersaCut Morcellator
37
Wolf Piranha Morcellator
Wolf Piranha Morcellator will be utilized for prostate tissue morcellation Wolf Piranha Morcellator
37
Total74

Baseline characteristics

CharacteristicWolf Piranha MorcellatorTotalLumenis VersaCut Morcellator
Age, Continuous69 years68.5 years68 years
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
United States
37 participants74 participants37 participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
37 Participants74 Participants37 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 370 / 37
other
Total, other adverse events
0 / 370 / 37
serious
Total, serious adverse events
0 / 370 / 37

Outcome results

Primary

Morcellation Rate

Operatively, the amount of enucleated tissue removed (in grams) per the time for complete removal (in minutes) will be recorded as morcellation rate.

Time frame: Collected intraoperatively upon completion of enucleation (surgical removal) of the extra benign prostate tissue growth

ArmMeasureValue (MEAN)
Lumenis VersaCut MorcellatorMorcellation Rate4.8 grams/minute
Wolf Piranha MorcellatorMorcellation Rate5.6 grams/minute

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026